Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Standard
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. / Budäus, Lars; Isbarn, Hendrik; Tennstedt, Pierre; Salomon, Georg; Schlomm, Thorsten; Steuber, Thomas; Haese, Alexander; Chun, Felix; Fisch, Margit; Michl, Uwe; Heinzer, Hans; Huland, Hartwig; Graefen, Markus.
in: BJU INT, Jahrgang 110, Nr. 11, 11, 12.2012, S. 1714-1720.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
AU - Budäus, Lars
AU - Isbarn, Hendrik
AU - Tennstedt, Pierre
AU - Salomon, Georg
AU - Schlomm, Thorsten
AU - Steuber, Thomas
AU - Haese, Alexander
AU - Chun, Felix
AU - Fisch, Margit
AU - Michl, Uwe
AU - Heinzer, Hans
AU - Huland, Hartwig
AU - Graefen, Markus
N1 - © 2012 BJU INTERNATIONAL.
PY - 2012/12
Y1 - 2012/12
N2 - Study Type--Prognosis (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Different tools allow the individual estimation of the various endpoints in patients with prostate cancer. The Cancer of the Prostate Risk Assessment (CAPRA) score is an easy to calculate prediction tool, based on a large population based database. However, little is known about the performance of this prediction tool in European patients. The data obtained in the present study demonstrate differences in tumour characteristics between European patients and the initial development cohort from the USA. However, the concordance index of the CAPRA scores for predicting biochemical recurrence and metastatic recurrence was 76.2 and 78.5, respectively, in European patients. Therefore, the CAPRA score also allows reliable prediction of the examined endpoints in European patients.
AB - Study Type--Prognosis (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Different tools allow the individual estimation of the various endpoints in patients with prostate cancer. The Cancer of the Prostate Risk Assessment (CAPRA) score is an easy to calculate prediction tool, based on a large population based database. However, little is known about the performance of this prediction tool in European patients. The data obtained in the present study demonstrate differences in tumour characteristics between European patients and the initial development cohort from the USA. However, the concordance index of the CAPRA scores for predicting biochemical recurrence and metastatic recurrence was 76.2 and 78.5, respectively, in European patients. Therefore, the CAPRA score also allows reliable prediction of the examined endpoints in European patients.
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Retrospective Studies
KW - Neoplasm Invasiveness
KW - Prostate/pathology
KW - Europe/epidemiology
KW - Risk Assessment/methods
KW - Prostate-Specific Antigen/metabolism
KW - Biopsy/methods
KW - Neoplasm Recurrence, Local/etiology/mortality
KW - Prostatic Neoplasms/mortality/pathology/surgery
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Retrospective Studies
KW - Neoplasm Invasiveness
KW - Prostate/pathology
KW - Europe/epidemiology
KW - Risk Assessment/methods
KW - Prostate-Specific Antigen/metabolism
KW - Biopsy/methods
KW - Neoplasm Recurrence, Local/etiology/mortality
KW - Prostatic Neoplasms/mortality/pathology/surgery
U2 - 10.1111/j.1464-410X.2012.11147.x
DO - 10.1111/j.1464-410X.2012.11147.x
M3 - SCORING: Journal article
C2 - 22520619
VL - 110
SP - 1714
EP - 1720
JO - BJU INT
JF - BJU INT
SN - 1464-4096
IS - 11
M1 - 11
ER -
